Introduction
Ovarian cancer is the leading cause of death from gynecological malignancies, with more than half of patients being diagnosed in the advanced stage. The overall 5year survival rate is around 40% in International Federation of Gynecology and Obstetrics (FIGO) stages III/IV and 90% in FIGO stage I. 1 The current standard of treatment for primary ovarian cancer is the combination of optimal cytoreductive surgery and platinumbased chemotherapy. Despite state of the art treatment, more than 50% of the patients will relapse and consequently die from this disease.
2 A curative approach is only possible in the primary situation. The aim of targeted 
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Braicu et al therapy is to prolong the tumorfree status achieved after the primary treatment. Recent data showed that some antiangiogenic therapies, eg, bevacizumab, are able to prolong progressionfree survival, thus no improvement in overall survival has been shown yet. 3, 4 There is an urgent need to identify new targets, and also biomarkers able to predict platinum response.
No macroscopic residual tumor mass after cytoreductive surgery is one of the major prognostic and predictive factors. Despite radical surgery, maximal tumor reduction cannot always be achieved. A neoadjuvant approach could have a benefit in this subgroup of patients, although data are controversial. [5] [6] [7] [8] Nevertheless, there are no effective biomarkers to predict surgi cal outcome in primary ovarian cancer patients.
HIF1α has been reported to be an important predictor of tumor progression for several types of solid cancers. [9] [10] [11] [12] [13] HIF1α is a major regulator of cell adaptation to hypoxic stress and plays a critical role in oncogenesis and angiogenesis. 14 This protein regulates the transcription of a number of genes involved in diverse biological functions such as proliferation, migration, invasion, apoptosis, and angiogenesis.
Immunohistochemical analysis of human cancer biop sies has shown that HIF1α is overexpressed in several solid malignancies, including breast, colon, lung, gastric, skin, and renal carcinomas, compared with their respective normal tissues. 15, 16 Like other tumors, overexpression of HIF1α has been detected in epithelial ovarian cancer. 15 Data regarding the clinical impact of HIF1α in ovarian cancer is still limited. Although HIF1α is detected in all epithelial ovarian cancer histological subtypes, higher HIF1α expression in clearcell carcinomas has been reported. 17, 18 The role of HIF1α in the development of new targeted therapies has been suggested by recent studies. 19, 20 Nakai et al stated that HIF1αexpressing tumors had a signifi cantly higher response rate to postoperative platinumbased chemotherapy than tumors without HIF1α expression. 21 However, the prognostic significance of HIF1α overex pression in ovarian cancer is still controversial. [21] [22] [23] [24] Until now, only limited data exist regarding the HIF1α predictive value in epithelial ovarian cancer.
The aim of this study was to investigate the impact of HIF1α expression in predicting surgical outcome, platinum response, and survival in patients with advanced primary epithelial ovarian cancer. Only patients with histologically confirmed ovarian cancer were included in the study. Due to better prognosis and sometimes different therapy strategies, FIGO stage I patients were excluded. All patients underwent cytoreductive surgery with maximal surgical effort and platinumbased chemotherapy. Inclusion and exclusion criteria for the study were reported in a recent publication. 25 An online database was used for the documentation of clinical, histopathological, and followup data. Residual tumor load was defined as nega tive if macroscopically absent. Overall survival was defined as the time from diagnosis of ovarian cancer to tumorrelated death or last contact. Progressionfree survival was defined as the interval from diagnosis to progression of disease or death, whereby progression was defined as an increase in the nadir serum CA125 level of at least two samples according to the Gynecological Cancer Intergroup criteria or radiological diagnosis according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Patients and methods

Documentation of clinical data
The tumor spread within the abdominal cavity was documented prospectively using the Intraoperative Mapping of Ovarian cancer -"IMO" tool. 26 The documen tation of residual tumor mass was also assessed prospec tively at the end of the surgery with an interview with the main surgeon. All data were documented in a validated online database.
The FIGO 2006 classification was used for clinical stag ing, and the Gynecologic Oncology Group criteria were used for histologic grading. 27 Response to treatment and diagnosis of recurrence was determined according to RECIST criteria 
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impact of hiF1α in patients with primary epithelial ovarian cancer or according to CA125 variations (Gynecological Cancer Intergroup criteria) during followup. 27, 28 Response to f irstline chemotherapy was def ined according to the last time patients received platinumbased compounds. Patients developing relapse within the first 6 months after platinum based chemotherapy were classi fied as platinumresistant; patients developing relapse after 6 months or more were classified as responders. 29 
collection of tumor tissue
Tumor tissue was removed from the patients during surgery and prior to chemotherapy treatment. Samples were snap frozen and stored in liquid nitrogen. At a later time, the tissue was processed to obtain lysate for protein measurement.
About 30 mg tumor tissue was homogenized with a MikroDismembrator and lysed in 1 mL Nucleic Acid Purification Lysis Solution (Thermo Fisher Scientific, Waltham, MA, USA).
hiF1α enzyme-linked immunosorbent assay (elisa)
HIF1α expression in tissue lysates was measured using the HIF1α ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's protocol. The assay was performed in duplicate for the calibrators, controls, and patient samples. The appropriate controls were within the ranges provided by the manufacturer.
statistical analysis
The clinical data were collected and entered in an online database. The statistical analysis was performed using IBM ® SPSS ® Statistics 21.0 (IBM Corporation, Armonk, NY, USA) at Charité -Medical University Berlin.
The prognostic factors used in the survival analysis were as follows: age at first diagnosis, FIGO stage, histological subtype, histological grade, presence and volume of ascites, residual tumor mass after surgery, peritoneal dissemination, and responses to platinumbased chemotherapy.
Kruskal-Wallis test, Spearman's rank correlation, Kendall's tau, and Mann-Whitney U test were used to assess the associations between HIF1α and other variables.
Receiver operating characteristic curve analysis was performed to evaluate the predictive accuracy of HIF1α expression for discriminating patients with maximal versus suboptimal residual tumor mass after surgery and platinum responders versus nonresponders.
Median survival and 95% confidence intervals (95% CI) were estimated according to the Kaplan-Meier method.
The logrank tests were used for univariate statistical comparisons and the Cox proportional hazard model was used to evaluate significant predictors of survival. Adjusted hazard ratios (HR) and 95% CI for prognostic factors were calculated. A twotailed Pvalue ,0.05 was considered sta tistically significant.
Results
Baseline characteristics
Most of the patients (86.2%) were diagnosed with serous ovarian cancer. Optimal debulking, ie, no evidence of mac roscopic tumor residuals, was reported in more than 60% of the patients. Patients' characteristics are presented in Table 1 , and are reported in greater detail elsewhere. 
Discussion
This study analyzed the role of HIF1α in primary ovarian cancer. The results showed that patients having tumors that overexpress HIF1α transcription factor (cutoff 80 pg/mg protein) are presenting a poorer prognosis.
One of the major bottlenecks in ovarian cancer management is the development of platinum resistance with 
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impact of hiF1α in patients with primary epithelial ovarian cancer subsequently increased mortality. The development of new targeted, especially antiangiogenic, drugs has translated into prolonged progressionfree survival without evidence of a positive impact on overall survival. The inhibition of neoan giogenesis in ovarian cancer leads to a certain hypoxia of the tumoral cells, and therefore increases apoptosis of tumoral cells. There are no in sufficient data to show a benefit in overall survival for patients being treated with antiangiogenic drugs. This might be caused by the capability of tumor cells to resist even hypoxic conditions. One of the mechanisms of chemotherapy resistance in solid tumors is the ability to develop a microenvironment caused by a poor and inefficient vascular supply. 30 The presence of hypoxia has been shown to be a marker for poor prognosis in many cancer types. The resistance to conventional chemotherapeutical drugs is caused by hypoxiainduced reduction in cell proliferation and also by the fact that hypoxic tumor cells reside some distance from the blood vessels, and therefore the drugs won't be able to reach their target. 31, 32 The homeostatic response to hypoxia is mediated by the transcription factor HIF1α, which is unstable in welloxygenated tissue but becomes stable under hypoxic conditions. 33 Due to hypoxic condi tions in tumoral tissue, as described previously, HIF1α is an important mediator for tumor invasion, metastasis, and chemotherapy resistance. 34 This study showed that HIF1α expression was indepen dent of FIGO stage, age, and grading. Mucinous and mixed epithelial carcinomas showed increased levels of HIF1α, although this association didn't reach statistical significance. Previously published data showed that clearcell carcinomas exhibit higher HIF1α levels than serous, mucinous, or endo metrioid tumors. 35, 36 Other studies suggest that HIF1α might be overexpressed in serous ovarian cancer. 24 The difference in the current results could be caused by low numbers of welldifferentiated (3.6%) and nonserous ovarian cancer patients included within the OVCAD study. More than that, differences in ethnicity might cause differences in the molecular biology of ovarian cancer. It is well known that clearcell ovarian cancer is more often encountered in Asian women compared to Caucasian women, and the clinical course of the disease is different. Clinical studies showed that chemotherapy or targeted therapy drugs are associated with different response rates and adverse effects in Caucasian and Asian populations. 37 Results similar to the current study were published by Nakayama et al, who reported that HIF1α levels were independent of clinical stage, age and histological sub types. 38 HIF1α expression was reported to be significantly stronger in good differentiated ovarian cancer. 17 The current results showed no significant correlation between HIF1α tissue expression and histological grading, which might be explained by the low number of welldifferentiated (G1) ovarian cancers included in this study. There was also no significant influence of HIF1α expression on response to platinumbased chemotherapy, this being in accordance with some existing results. 17 However, Nakai et al reported that tumors expressing higher HIF1α more likely respond to platinumbased chemotherapy compared with tumors with no or poor HIF1α expression. 21 The current study analyzed the expression of HIF1α in 275 patients with FIGO stage II-IV, but Nakai et al's study only included 52 stage III-IV epithelial ovarian cancer patients.
HIF1α increased tissue values were associated with shorter progressionfree survival, but this was not statistically significant, which agrees with recent studies. 22 , 23 Daponte et al observed that the median progressionfree survival of HIF1αpositive patients was shorter, but not statistically significant. 22 In lung and colorectal carcinomas, HIF1α had no impact on patient survival, but overexpression of HIF2α was a prognostic indicator. 39, 40 In ovarian carcinomas, Birner et al showed that HIF1α overexpression alone was not a prognostic indicator and became a strong prognostic marker in combination with functional p53 protein.
17
Conclusion
The current study showed that HIF1α tissue expression might impact the overall survival in primary ovarian cancer patients treated by cytoreductive surgery and platinumbased chemotherapy. No correlation between HIF1α tissue expres sion and platinum response and no significant statistical dif ference between HIF1α expression in different histological subtypes was found. Further studies analyzing the role of this transcriptional factor in a larger prospective cohort of patients are warranted. Studies analyzing the HIF1α distribution within tumor tissue using immunochemistry are needed.
Drugs interfering with the HIF1α pathway, such as ganetespib, 41 are currently under evaluation in clinical studies. Targeting HIF1α might be a way to improve survival in ovarian cancer patients.
